Adverse effects of meglumine diatrizoate on renal function in the early post-transplant period.
Thirty-four renal transplant recipients received drip infusion urograms from 2-24 days post-transplantation. Twenty-two patients exhibited changes in renal function within 1-4 days of the urogram that were indistinguishable from allograft rejection: a tender, swollen kidney, elevation of serum creatinine, oliguria, decreased urine sodium concentration, weight gain, and hypertension. Two patients developed acute tubular necrosis and required hemodialysis, but renal function in the remaining 20 patients improved after therapy for "graft rejection" with i.v. methyprednisolone sodium succinnate. Kidneys from older-age donors that were functioning suboptimally and kidneys which exhibited subsequent clinical allograft rejection were more at risk for contrast media toxicity. This suggests that occult vascular lesions may have been present in the allograft which were exacerbated when exposed to the irritant vascular effects of contrast media, producing a mild, reversible toxic nephritis. However, several kidneys with normal function and several kidneys which never exhibited rejection activity were also adversely affected by exposure to contrast media. It appears these agents should be used cautiously, if at all, in the early post-transplant period.
D003404:Creatinine / Q000097:blood; D003609:Dactinomycin / Q000627:therapeutic use; D003973:Diatrizoate / Q000031:analogs & derivatives*; D003974:Diatrizoate Meglumine / Q000009:adverse effects*; D006084:Graft Rejection / Q000528:radiation effects; D006801:Humans; D007668:Kidney / Q000000981:diagnostic imaging / Q000503:physiopathology*; D016030:Kidney Transplantation; D008775:Methylprednisolone / Q000627:therapeutic use; D011183:Postoperative Complications; D011859:Radiography; D011878:Radiotherapy; D013997:Time Factors; D014184:Transplantation, Homologous
D003973:Diatrizoate; D003609:Dactinomycin; D003974:Diatrizoate Meglumine; D003404:Creatinine; D008775:Methylprednisolone